Staging COPD is not a single test or a single number. It involves layering several measurements on top of each other: how much air you can push out of your lungs in one second, how breathless you feel during daily activities, how often your symptoms flare up, and increasingly, what your blood and imaging scans reveal about inflammation patterns. The system most clinicians worldwide rely on comes from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), which has evolved considerably over the past two decades from a simple spirometry-only scale into a multidimensional framework that shapes treatment decisions at every step.
The Spirometry Foundation
Every COPD staging conversation starts with spirometry, a breathing test that measures how fast and how completely you can exhale after a full breath. Two numbers matter most: FEV1, the volume of air forced out in the first second, and FVC, the total volume you can exhale. A ratio of FEV1 to FVC below 0.70 after inhaling a bronchodilator confirms the presence of airflow obstruction and establishes the COPD diagnosis itself.1Respiratory Care. Increased Accuracy After Adjustment of Spirometry Threshold for Diagnosing COPD Based on Pre-Bronchodilator FEV1/FVC The measurement must be taken after bronchodilator use to ensure the obstruction is not fully reversible, which would point toward asthma instead.2European Respiratory Journal. GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD
Once obstruction is confirmed, severity is graded by how far your FEV1 has fallen relative to what is predicted for someone of your age, height, and sex. The GOLD system divides this into four grades:3BMJ Open Respiratory Research. Comparison of stability of the GOLD and STAR lung function classification for chronic obstructive pulmonary disease
- GOLD 1 (Mild): FEV1 at or above 80% of predicted. Many people at this stage do not even realize they have COPD.
- GOLD 2 (Moderate): FEV1 between 50% and 79% of predicted. Breathlessness during exertion usually becomes noticeable.
- GOLD 3 (Severe): FEV1 between 30% and 49% of predicted. Everyday tasks like climbing stairs or carrying groceries become difficult.
- GOLD 4 (Very severe): FEV1 below 30% of predicted. Quality of life is substantially impaired, and flare-ups can be life-threatening.
These grades remain clinically useful, but they tell only part of the story. Two people with the same FEV1 can have wildly different symptom burdens, exercise tolerance, and rates of flare-ups. That gap between the number on the spirometer and the person’s lived experience is what drove GOLD to build a broader assessment framework on top of the lung-function grades.
Measuring Symptoms and Breathlessness
GOLD guidelines recommend assessing symptoms using one of two standardized tools: the modified Medical Research Council (mMRC) dyspnea scale or the COPD Assessment Test (CAT).4PubMed Central. COPD exacerbations associated with the modified Medical Research Council scale and COPD assessment test among Humana Medicare members The mMRC is a five-point breathlessness scale, where 0 means you only get breathless with strenuous exercise and 4 means you are too breathless to leave the house or dress yourself. The CAT is an eight-question survey covering cough, phlegm, chest tightness, breathlessness on hills or stairs, activity limitations, confidence leaving home, sleep quality, and energy. Scores range from 0 to 40, with 10 or above generally indicating a high symptom burden.
The two tools correlate with each other, but they do not always agree. One study found that roughly a fifth of patients fell into different symptom categories depending on which tool was used, with some patients scoring low on breathlessness but high on overall symptom burden (or vice versa).5PubMed Central. How to Utilize CAT and mMRC Scores to Assess Symptom Status of Patients with COPD in Clinical Practice? The practical takeaway is that if either score flags high symptoms, that should be enough to place you in a higher symptom group. But confirming low symptoms ideally requires checking both scales, since the mMRC captures only breathlessness while the CAT picks up a broader range of complaints.6PubMed Central. Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting
The ABE Classification and What It Means for Treatment
GOLD’s current combined assessment groups symptoms and exacerbation history into three categories rather than four. Previously labeled A through D, the system was simplified to A, B, and E. Group A means fewer symptoms and few flare-ups. Group B means more symptoms but still low exacerbation risk. Group E covers anyone with frequent or severe exacerbations, regardless of symptom level. The “E” stands for exacerbation, and the change was made because the old Group C and D distinction often confused clinicians without meaningfully changing prescribing patterns.
The latest GOLD revisions have continued refining this framework, recognizing disease activity as a therapeutic target and adjusting the exacerbation thresholds that place a patient in Group E.7PubMed Central. GOLD 2026: Transforming COPD Management with Early Intervention, Multi-dimensional Assessment, and Personalized Care A study examining how well different exacerbation cutoffs predict future flare-ups found that proposed grading refinements offered meaningfully better prediction of moderate exacerbations over one and four years compared to the older criteria.8JAMA Network Open. GOLD COPD Exacerbation History Categories and Disease Outcomes The staging conversation is still evolving, in other words, and what counts as “frequent” exacerbations may shift as better data come in.
Why Exacerbation History Carries So Much Weight
Flare-ups are not just bad days. Frequent exacerbations accelerate the long-term decline in lung function, reduce exercise capacity, and increase the risk of death.9PubMed Central. Impact of exacerbations on COPD Even among people who have quit smoking, those who experience frequent exacerbations lose lung function faster than those who flare up less often.10PubMed. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers This is the central reason exacerbation history now anchors one entire axis of the staging grid: it is the strongest single predictor of future exacerbations, which in turn are the strongest driver of disease progression beyond what the FEV1 alone would predict.
This also means that staging is not static. Someone who goes a year without a flare-up might shift from Group E to Group B. Conversely, someone whose exacerbations increase in frequency after a respiratory infection could move into Group E and need more aggressive therapy. Clinicians are encouraged to reassess staging at regular intervals rather than treating it as a permanent label.
Blood Eosinophils and the Role of Biomarkers
One of the more consequential additions to COPD staging in recent years is the blood eosinophil count. Eosinophils are a type of white blood cell involved in certain inflammatory pathways, and their levels in a routine blood draw help predict whether inhaled corticosteroids (ICS) will be effective at reducing flare-ups. A systematic review and meta-analysis found that patients with blood eosinophils at or above 2% who received ICS therapy had about a 17% reduction in moderate-to-severe exacerbations compared to those not on ICS, though the same eosinophil-high patients also faced an increased risk of pneumonia.11PubMed Central. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis
Higher eosinophil counts at baseline consistently predict a stronger response to ICS across multiple trials.12PubMed Central. Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects GOLD now formally integrates blood eosinophil counts into its treatment algorithms for Group E patients: those with higher counts are directed toward ICS-containing regimens, while those with low counts are steered toward non-ICS options. The eosinophil count does not change the staging group itself, but it profoundly shapes what treatment that stage calls for.
CT Imaging and Structural Phenotyping
Spirometry tells you how the lungs perform; CT imaging tells you what they look like inside. Quantitative CT can distinguish between emphysema-dominant disease, where the air sacs themselves are destroyed, and airway-dominant disease, where the bronchial walls are thickened and inflamed. These are not academic curiosities. A study of over 400 COPD patients identified four CT phenotypes: normal-appearing, emphysema-dominant, airway-dominant, and a mixed type showing both emphysema and airway wall thickening.13PubMed Central. Mixed Phenotype of Emphysema and Airway Wall Thickening Is Associated with Frequent Exacerbation in Chronic Obstructive Pulmonary Disease Patients The mixed phenotype had the worst symptom scores, the lowest FEV1, and a rate of severe exacerbations over four times higher than the CT-normal group.
CT measures of emphysema and airway wall thickness also relate to specific symptoms. People with more emphysema tend to report worse breathlessness, while thicker airway walls are linked to more cough and wheezing, independent of how low the FEV1 is.14American Journal of Respiratory and Critical Care Medicine. Quantitative Computed Tomography Measures of Emphysema and Airway Wall Thickness Are Related to Respiratory Symptoms CT phenotyping is not yet part of routine GOLD staging, but it is increasingly used in research and specialized clinics to guide decisions about surgical options like lung volume reduction and to identify patients whose disease trajectory may not match their spirometry numbers.
Exercise Testing and Functional Capacity
A simple walk test can reveal information about COPD severity that spirometry misses. The six-minute walk test (6MWT) is the most widely used: you walk as far as you can in six minutes on a flat corridor while your oxygen levels and heart rate are monitored. A substantial number of people with stable COPD who maintain normal oxygen saturation at rest drop below safe levels during walking. In one study, more than half of stable COPD patients desaturated during the 6MWT, and a resting oxygen saturation at or below 93% predicted this drop with about 83% sensitivity.15PubMed Central. Exercise-induced desaturation in patients with chronic obstructive pulmonary disease on six-minute walk test
Beyond oxygen levels, exercise testing helps explain why some people with mild COPD feel disproportionately breathless. Patients with even GOLD 1 disease who have a low diffusing capacity (DLCO), a measure of how efficiently the lungs transfer gas, report significantly more exertional breathlessness than those with preserved DLCO. The reduced gas exchange forces the lungs to work harder to maintain oxygen delivery during exercise, and this extra ventilatory demand triggers breathlessness at lower workloads.16PubMed. Mechanisms of Exertional Dyspnea in Patients with Mild COPD and a Low Resting DLCO In moderate to severe disease, DLCO appears to be a better predictor of exercise capacity than FEV1 alone.17PubMed Central. Influence of resting lung diffusion on exercise capacity in patients with COPD
PRISm and the Question of Pre-COPD
Not everyone with abnormal spirometry fits neatly into the GOLD 1–4 grades. Some people show a reduced FEV1 (below 80% of predicted) but a preserved FEV1/FVC ratio, meaning the 0.70 threshold that defines COPD is not crossed. This pattern, called Preserved Ratio Impaired Spirometry (PRISm), is increasingly recognized as a clinically important category.18PubMed Central. Preserved ratio impaired spirometry: clinical, imaging and artificial intelligence perspective PRISm is more common in people with higher body mass, current smokers, and women, and it frequently coexists with metabolic disorders and cardiovascular disease.
The trajectory of PRISm is what makes it matter for staging. A population-based study found that among people re-examined over time, about half of those with PRISm eventually developed COPD, while roughly one in six returned to normal spirometry.19European Respiratory Journal. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study People with PRISm had increased all-cause and cardiovascular mortality at rates comparable to those with moderate-to-severe COPD. The group appears to include at least three distinct subsets: future COPD developers, people with high cardiovascular burden and early death, and those who maintain stable lung function over time. Current GOLD reports now acknowledge PRISm as a form of pre-COPD, and there is growing interest in identifying and monitoring these individuals before they cross the diagnostic threshold.
Two Pathways to COPD
The staging framework assumes that COPD results from progressive lung damage over time, but research has shown that there are at least two distinct pathways. A landmark study tracking lung function over 22 years found that roughly half of the people who eventually had COPD had started with normal lung function in early adulthood and experienced an accelerated decline. The other half, though, had low FEV1 before the age of 40 and then declined at a fairly normal rate; their disease reflected an early developmental deficit rather than accelerated loss.20PubMed. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease The two groups had similar smoking histories but arrived at COPD through fundamentally different biological routes.
This has implications for how staging is interpreted in younger patients. A 45-year-old with GOLD 2 disease who never reached full lung growth has a different prognosis and potentially different treatment needs than a 65-year-old who reached peak lung function and then lost it rapidly. Current staging tools do not distinguish between these trajectories, but the research suggests they probably should.
Sex Differences in COPD Staging
Women with COPD tend to report greater breathlessness and higher morbidity compared to men at similar spirometric stages.21PubMed Central. Sex-differences in COPD: from biological mechanisms to therapeutic considerations A large French cohort study found that women had nearly double the odds of experiencing two or more exacerbations per year and were more likely to be classified in the high-exacerbation Group E. Yet men had significantly higher mortality at every level of airflow obstruction.22PubMed Central. Sex Differences and Survival Among COPD Patients in France: The Palomb Cohort The determinants of exacerbation risk and death were different between sexes, suggesting that the same staging label may mean somewhat different things depending on whether the patient is male or female.
Biologically, women tend to have smaller airways relative to lung size, and hormonal factors may influence inflammatory responses. There is also a diagnostic bias: women with COPD are more often misdiagnosed with asthma, which can delay proper staging and treatment. The current staging tools are sex-neutral, and there is no consensus yet on whether sex-specific thresholds would improve outcomes, but the differences are large enough that clinicians increasingly take sex into account when interpreting staging results.
Cardiovascular Comorbidity and Its Staging Implications
Heart disease does not just coexist with COPD; it reshapes the disease’s trajectory. A large proportion of patients with mild and moderate COPD die from cardiovascular causes rather than respiratory failure.23PubMed Central. Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients A 15-year follow-up study found that COPD patients with comorbid heart disease had roughly 1.5 times the risk of hospitalization for any cause and nearly twice the all-cause mortality risk, with cardiovascular death risk more than tripled.24PubMed Central. Comorbid Heart Disease in Patients with COPD is Associated with Increased Hospitalization and Mortality – A 15-Year Follow-Up Interestingly, heart disease did not significantly increase the risk of respiratory hospitalization or respiratory death specifically, suggesting that the two diseases drive separate streams of harm.
This matters for staging because GOLD grades and ABE groups capture respiratory severity but not cardiovascular risk. A patient in GOLD 2, Group A might appear low-risk based on the staging grid yet face substantial mortality from coexisting heart failure. Clinicians who manage COPD in isolation risk missing the bigger picture. There is growing recognition that comorbidity profiling belongs alongside spirometry and exacerbation history in any meaningful assessment of disease severity.
Muscle Loss and the Systemic Side of COPD
COPD does not stay in the lungs. As the disease progresses and physical activity declines, muscle wasting (sarcopenia) becomes common. Reduced activity leads to loss of muscle mass, which in turn makes it harder to use oxygen efficiently, which further reduces exercise tolerance in a self-reinforcing cycle.25PubMed Central. Sarcopenia Associated with Chronic Obstructive Pulmonary Disease Patients with both COPD and sarcopenia walk shorter distances on shuttle walk tests and have weaker respiratory and grip strength.26Jornal Brasileiro de Pneumologia. Pulmonary function and functional capacity cut-off point to establish sarcopenia and dynapenia in patients with COPD
Sarcopenia does not currently factor into GOLD staging, but it profoundly affects prognosis. Composite indices like the BODE index, which combines body mass index, airflow obstruction, dyspnea, and exercise capacity, were developed partly to capture these extrapulmonary dimensions. Though the BODE index has been widely used for prognostication, its calibration has been inconsistent across populations, with one validation study finding that it underpredicted three-year mortality risk by about a third in one cohort and overpredicted by a similar margin in another.27The Lancet. Validation and updating of the BODE index for exacerbations and mortality rates in COPD
The Overlap With Sleep-Disordered Breathing
Nighttime is when COPD can quietly cause the most damage. Normal sleep reduces breathing drive and relaxes upper airway muscles, which is harmless for most people but dangerous for someone whose lungs are already compromised. COPD patients who also have obstructive sleep apnea, a combination sometimes called overlap syndrome, face a compounding effect. The Sleep Heart Health Study found that people with both conditions spend significantly more time with dangerously low oxygen levels at night than those with sleep apnea alone, and the degree of airflow obstruction as measured by FEV1/FVC correlates directly with the severity of overnight hypoxemia.28PubMed Central. Sleep-Disordered Breathing and COPD: The Overlap Syndrome
A recent study added further nuance, finding that COPD independently added over 46 extra minutes of time spent below 88% oxygen saturation per night, while sleep apnea added about 10 minutes. When periodic limb movements during sleep were layered on top of both conditions, the combined burden was even greater than the sum of the parts.29PubMed Central. Nocturnal hypoxemia in COPD: the amplifying effect of comorbid OSA and PLMS on oxygen desaturation Cardiovascular outcomes track closely with this nocturnal hypoxemia: COPD patients spending at least 10 minutes of sleep with oxygen saturation below 90% had roughly double the hazard of cardiovascular events.30Annals of the American Thoracic Society. Cardiovascular Outcomes and All-Cause Mortality in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease (Overlap Syndrome) Sleep studies are not part of routine COPD staging, but for patients with more advanced disease or unexplained cardiovascular deterioration, screening for overlap syndrome can uncover a treatable contributor that spirometry alone would never detect.
Wearable Technology and Early Exacerbation Detection
One of the most frustrating aspects of COPD staging is that it typically happens in a clinic, using snapshots of lung function and recalled symptom histories, while the disease itself fluctuates day to day. Wearable devices that continuously track oxygen saturation, heart rate, and physical activity are starting to fill that gap. A systematic review of wearable interventions in COPD found that continuous pulse oximetry and heart rate monitoring could predict exacerbations before symptoms became obvious, with one telehealth system combining wearables and air quality data achieving 94% sensitivity for early exacerbation detection.31PubMed Central. Wearable technology interventions in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
A separate study developed a risk score based on wearable vital sign monitoring that could flag moderate and severe exacerbations an average of about four days before they occurred, with an overall accuracy of roughly 85%.32PLOS Digital Health. Short-term prediction of COPD exacerbations based on wearable vital sign monitoring If these tools become routine, the concept of staging itself may shift from a periodic clinic assessment to something closer to continuous monitoring, where your “stage” is updated in real time based on trends in oxygen levels, activity, and physiological stress rather than a spirometry number from three months ago.